BRAF Codon 600 Mutation Detection by Pyrosequencing (Change effective as of 05/20/24: Refer to 3017203)
Also known as: BRAF PCR
Use
This test detects mutations in BRAF codon 600 (exon 15), including hotspot SNVs, MNVs, and small insertions/deletions (1–25 bp), which have diagnostic, prognostic, and therapeutic implications in various solid tumors, such as colorectal cancer, melanoma, and lung cancer. It may assist in determining eligibility for targeted therapies and in screening for Lynch syndrome.([arupconsult.com](https://www.arupconsult.com/node/23289?utm_source=openai))
Special Instructions
Change effective as of May 20, 2024: refer to test 3017203 for updated methodology and details.([ltd.aruplab.com](https://ltd.aruplab.com/Tests/Pub/2002498))
Limitations
This assay does not detect variants outside the targeted hotspot region or below the limit of detection. It does not detect copy number alterations, translocations, TMB, MSI, deep intronic variants, RNA variants, or large indels (>25 bp). It cannot distinguish between somatic and germline variants. Variants near the limit of detection may not be reliably identified due to technical constraints like pseudogenes, GC‑rich regions, and primer overlap. Tissue samples with low DNA input (1–5 ng) may yield suboptimal results and require client‑approved disclaimers. Benign or likely benign variants are not reported; VAF is not reported. Results must be interpreted within clinical context and the test is not for minimal residual disease.([arupconsult.com](https://www.arupconsult.com/node/23289?utm_source=openai))
Methodology
Mass Spectrometry
Biomarkers
Result Turnaround Time
10-15 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided